Camurus AB (publ)
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029… Read more
Camurus AB (publ) (CAMRF) - Total Liabilities
Latest total liabilities as of June 2025: $553.52 Million USD
Based on the latest financial reports, Camurus AB (publ) (CAMRF) has total liabilities worth $553.52 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Camurus AB (publ) - Total Liabilities Trend (2014–2024)
This chart illustrates how Camurus AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Camurus AB (publ) Competitors by Total Liabilities
The table below lists competitors of Camurus AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WuXi XDC Cayman Inc.
F:L74
|
Germany | €3.18 Billion |
|
NBT Bancorp Inc
NASDAQ:NBTB
|
USA | $14.10 Billion |
|
Wuchan Zhongda Group Co Ltd
SHG:600704
|
China | CN¥164.05 Billion |
|
Zabka Group S.A.
WAR:ZAB
|
Poland | zł17.19 Billion |
|
Zhejiang Yongtai Technology Co Ltd
SHE:002326
|
China | CN¥8.21 Billion |
|
PennyMac Financial Services Inc
F:1AC
|
Germany | €21.19 Billion |
|
Zhejiang Sanmei Chemical Industry Co Ltd
SHG:603379
|
China | CN¥1.63 Billion |
|
Porsche AG
XETRA:P911
|
Germany | €30.84 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Camurus AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Camurus AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Camurus AB (publ) (2014–2024)
The table below shows the annual total liabilities of Camurus AB (publ) from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $467.33 Million | +12.66% |
| 2023-12-31 | $414.82 Million | +33.46% |
| 2022-12-31 | $310.82 Million | +33.40% |
| 2021-12-31 | $232.99 Million | +18.47% |
| 2020-12-31 | $196.66 Million | +40.06% |
| 2019-12-31 | $140.41 Million | +24.92% |
| 2018-12-31 | $112.40 Million | +23.61% |
| 2017-12-31 | $90.93 Million | +20.67% |
| 2016-12-31 | $75.36 Million | -57.13% |
| 2015-12-31 | $175.79 Million | +108.75% |
| 2014-12-31 | $84.21 Million | -- |